Ovid Therapeutics Inc. (OVID) Cash Flow Statement

The OCF/NI ratio has been volatile, swinging from 1.17 in 2026Q2 to -1.67 in 2024Q2, indicating that reported net income is not a reliable proxy for cash generation. The persistent negative operating cash flow, even in quarters with positive net income (e.g., 2025Q4), underscores that the business is not yet self-funding. This disconnect is a critical red flag for a pre-commercial biotech, as it highlights the reliance on external financing to fund operations.

The FCF trajectory shows no signs of improvement, with the deficit widening from -$10.0M in 2024Q4 to -$17.6M in 2026Q2. This deterioration is particularly concerning given the company's negligible capital expenditures, meaning the entire cash burn is driven by operating losses. The trend suggests that without a significant revenue inflection or cost reduction, the company's cash reserves will continue to deplete at an accelerating rate.

The volatility in working capital, such as the $134K inflow in 2025Q4 and the $2.1M outflow in 2026Q2, adds noise to the operating cash flow line and makes forecasting more difficult. For a company with minimal revenue, these swings are likely driven by the timing of milestone payments or grant receipts rather than operational efficiency. This unpredictability complicates liquidity management and underscores the need for a larger cash buffer.

The absence of any capital return or strategic investment is a direct consequence of the company's pre-commercial stage and negative cash flow profile. With operating cash flow consistently negative, management's sole focus appears to be preserving liquidity for R&D and operations. This lack of deployment is not a choice but a necessity, and it will persist until the company achieves positive cash flow or secures additional financing.